Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Souroubea + platanus is a botanical combination product developed primarily for the treatment of anxiety and noise-induced stress, such as thunderstorm phobia, in companion animals, specifically dogs. The formulation consists of extracts from the tropical Neotropical plant *Souroubea sympetala* and the North American sycamore *Platanus occidentalis*. The primary active therapeutic component in *Souroubea* is betulinic acid, which has been identified as a positive allosteric modulator of the GABA-A receptor, thereby enhancing inhibitory neurotransmission in the central nervous system to produce anxiolytic effects. The *Platanus occidentalis* component is included for its synergistic properties, which may involve enhancing the bioavailability or efficacy of the triterpenes found in *Souroubea*. This combination was developed through collaborative research at the University of Ottawa and the National Research Council of Canada as a natural alternative to traditional pharmaceutical anxiolytics like benzodiazepines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on souroubea + platanus.